These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26122235)

  • 1. EVALUATION OF ANTIVIRAL THERAPY TREATMENT FOR LIVER CIRRHOSIS CAUSED BY CHRONIC HEPATITIS C AND HEPATITIS C BY 31P-MRS, BASED ON METABOLITE DETECTION.
    Gu JS; Sun RR; Shen S; Yu ZJ
    J Biol Regul Homeost Agents; 2015; 29(2):443-50. PubMed ID: 26122235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo and in vitro 31P magnetic resonance spectroscopy of focal hepatic malignancies.
    Cox IJ; Bell JD; Peden CJ; Iles RA; Foster CS; Watanapa P; Williamson RC
    NMR Biomed; 1992; 5(3):114-20. PubMed ID: 1322688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cirrhosis of the human liver: an in vitro 31P nuclear magnetic resonance study.
    Taylor-Robinson SD; Thomas EL; Sargentoni J; Marcus CD; Davidson BR; Bell JD
    Biochim Biophys Acta; 1995 Oct; 1272(2):113-8. PubMed ID: 7548234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
    Morisco F; Amoruso D; Stroffolini T; Caporaso N
    Dig Liver Dis; 2008 May; 40(5):391-2. PubMed ID: 18291731
    [No Abstract]   [Full Text] [Related]  

  • 8. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
    Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
    Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peg-IFNa-2a/RBV antiviral efficacy in cirrhotic hepatitis C patients after splenectomy or partial splenic embolization].
    Xie YM; Li B; Ma L; Pan L; Wei X; Peng XJ; Hao CQ; Zhang Y; Bai XF; Kang WZ; Jia ZS
    Zhonghua Gan Zang Bing Za Zhi; 2012 Feb; 20(2):112-5. PubMed ID: 22464782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy.
    D'Ambrosio R; Aghemo A; Rumi MG; Primignani M; Dell'Era A; Lampertico P; Donato MF; De Nicola S; Prati GM; de Franchis R; Colombo M
    Antivir Ther; 2011; 16(5):677-84. PubMed ID: 21817189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.
    Jeon MJ; Lee Y; Ahn S; Lee C; Kim OH; Oh BC; Yu U; Kim H
    Acta Radiol; 2015 Sep; 56(9):1051-60. PubMed ID: 25270373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
    Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
    Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M; Berg T
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
    Kornberg A; Küpper B; Tannapfel A; Thrum K; Bärthel E; Habrecht O; Settmacher U
    Transplantation; 2008 Aug; 86(3):469-73. PubMed ID: 18698252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA
    Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
    Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PEG-interferons: significance for the treatment of viral hepatitis B and C].
    Wedemeyer H; Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2001 Jun; 126 Suppl 1():S68-75. PubMed ID: 11450618
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
    Nair S; Lipscomb J; Eason J
    Transplantation; 2008 Aug; 86(3):418-22. PubMed ID: 18698245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.